1.Marsden, CD, Parkes, JD. “On-off” effects in patients with Parkinson’s disease in chronic levodopa therapy. Lancet 1976; 1: 292–296.
2.Lewitt, PA, Chase, TN. “On-off” effects; the new challenge in
parkinsonism. Trends Neurosci 1983; 6: 1–4.
3.Fahn, S. Fluctuations of disability in Parkinson’s disease: Patho-physiology. In: Movement Disorders, ed. Marsden, CD and Fahn, S. Butterworth, London 1982; 123–145.
4.Marsden, CD, Parkes, JD, Quinn, N. Fluctuations of disability in Parkinson’s disease: Pathophysiological aspects. In: Movement Disorders. Marsden, CD and Fahn, S, eds. Butterworth, London 1982; 96–122.
5.Fahn, S. Episodic failure of absorption of L-dopa: A factor in the control of clinical fluctuations in the treatment of parkinsonism. Neurology 1977; 27 (suppl 2): 390.
6.Melamed, E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch of Neurology 1986; 43: 402–405.
7.Schwab, RS, Amador, LV, Lettvin, JY. Apomorphine in Parkinson’s disease. Trans Amer Neurol Assoc 1951; 76: 2512–2513.
8.Nutt, JG, Fellman, JH. Pharmacokinetics of levodopa. Clin Neuro-pharm 1984; 7: 35–50.
9.Gervas, JJ, Muradas, V, Bazan, E, et al. Effects of 3-OM-dopa on monamine metabolism in rat brain. Neurology (Cleveland) 1983; 33: 278–282.
10.Reches, A, Nuelke, LR, Fahn, S. 3-0-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology (NY) 1983; 32: 887–888.
11.Sthal, S. Applications of new drug delivery technologies to Parkinson’s disease and dopaminergic agents. J Neural Trans (in press).
12.Obeso, JA, Sthal, S. New routes of administration for antiparkinsonian therapy. “Drugs for the treatment of Parkinson’s disease”. Calne, DB, Springer-Verlag, Berlin (in press).
13.Shoulson, I, Glaubiger, GA, Chase, TN. On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975: 25: 1144–1148.
14.Rosin, AJ, Devereux, D, Calne, DB. Parkinsonism with “on-off” phenomena-intravenous treatment with levodopa after major abdominal surgery. Arch Neurol 1979; 36: 32–34.
15.Quinn, NP, Parkes, JD, Marsden, CD. Control of “on-off” phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34: 1131–1136.
16.Hardie, RJ, Lees, AJ, Stern, GM. On-off fluctuations in Parkinson’s disease: A clinical and neuropharmacological study. Brain 1984; 107: 487–506.
17.Nutt, JG, Woodward, WR, Hammerstad, JP, et al. The “on-off” phenomenon in Parkinson’s disease. New Eng J Med 1984; 310: 483–488.
18.Marion, MH, Stocchi, F, Quinn, NP, et al. Repeated levodopa infusions in fluctuating Parkinson’s disease: Clinical and pharmacokinetic data. Clin Neuropharm 1986; 9: 165–181.
19.Chase, TN, Mouradian, MM, Fabbrini, G, et al. Pathogenetic studies of motor fluctuations in Parkinson’s disease. J Neurol Trans (in press).
20.Luquin, MR, Obeso, JA, Martinez Lage, JM, et al. Levodopa and 3-0-Methyldopa plasma levels in Parkinson’s disease: Patients with clinical fluctuations versus smooth responders. Neurology 1986; 36 (supp 1): 244.
21.Cooper, DR, Marrel, C, Testa, B, et al. L-Dopa Methyl Ester: A candidate for chronic systemic deli very of L-Dopa in Parkinson’s disease. Clin Neuropharm 1984; 7: 88–98.
22.Obeso, JA, Martinez Lage, JM, Luqwuin, MR. Lisuride infusion for Parkinson’s disease. Ann Neurol 1983; 14: 134.
23.Obeso, JA, Luquin, MR, Martinez Lage, JM. Intravenous lisuride corrects motor oscillations in Parkinson’s disease. Ann Neurol 1986a; 19: 31–35.
24.Luquin, MR, Obeso, JA, Martinez Lage, JM, et al. Parenteral administration of lisuride in Parkinson’s disease. Adv Neurol 1987: 45.
25.Obeso, JA, Luquin, MR, Martinez Lage, JM. Lisuride infusion pump: A device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1986b; 1: 467–470.
26.Obeso, JA, Luquin, MR, Vaamonde, J, et al. Continuous subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson’s disease. J Neural Trans (in press).
27.Critchley, P, Grandas, F, Quinn, N, et al. Continuous subcutaneous lisuride infusions in Parkinson’s disease. J Neural Trans (in press).
28.Ruggieri, S, Stocchi, F, Agnoli, A. Lisuride infusion pump for Parkinson’s disease. Lancet 1986; 11: 348–349.
29.Vaamonde, J, Obeso, JA, Luquin, R. Increased levodopa consumption reduces motor response to apomorphine in Parkinson’s disease. Neurology 1987; (suppl 1): 37.
30.Cotzias, GC, Mena, I, Papavasilious, PS. Overview of present treatment of parkinsonism with levodopa. Adv Neurol 1973; 2: 265–277.
31.Winkler, JD, Weiss, B. Reversal of supersensitivity apomorphine induced rotational behaviour in mice by continuous exposure to apomorphine. J Phar Exp Therap 1986; 238: 242–247.
32.Stoessl, AJ, Mak, E, Calne, DB. (+)-4-propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism. Lancet 1985; 2: 1330–1331.
33.Grandas Perez, F, Jenner, J, Nomoto, M, et al. (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson’s disease. Lancet 1986; 1: 906.
34.Coleman, RJ, Grandas Perez, F, Quinn, N, et al. 4-propyl-9-hydroxy-naphthoxazine in Parkinson’s disease and MPTP models (in press).